<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875523</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A2102</org_study_id>
    <secondary_id>2013-001875-18</secondary_id>
    <nct_id>NCT01875523</nct_id>
  </id_info>
  <brief_title>PK of Serelaxin in Severe Renal Impairment and ESRD</brief_title>
  <acronym>CRLX030A2102</acronym>
  <official_title>A Single Dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of Serelaxin in Patients With Severe Renal Impairment or End-Stage Renal Disease on Hemodialysis Compared to Matched Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the pharmacokinetics, safety and tolerability,&#xD;
      immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with&#xD;
      severe renal impairment and end-stage-renal-disease (ESRD) compared to healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15</time_frame>
    <description>Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the serum concentration-time curve from time zero to 28 hours after administration (AUC 0-28hr)</measure>
    <time_frame>pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15</time_frame>
    <description>Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the serum concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15</time_frame>
    <description>Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The observed maximum serum concentration following drug administration (Cmax)</measure>
    <time_frame>pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15</time_frame>
    <description>Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with reported adverse events, serious adverse events and death.</measure>
    <time_frame>From Day -21 to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients developing anti-RLX030 antibodies</measure>
    <time_frame>Day 1 (pre-treatment) and Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Renal Failure, Chronic</condition>
  <condition>End-Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Group 1 Treatment with serelaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Treatment with serelaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Treatment with serelaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Treatment with serelaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <arm_group_label>Group 1 Treatment with serelaxin</arm_group_label>
    <arm_group_label>Group 2 Treatment with serelaxin</arm_group_label>
    <arm_group_label>Group 3 Treatment with serelaxin</arm_group_label>
    <arm_group_label>Group 4 Treatment with serelaxin</arm_group_label>
    <other_name>RLX030</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
        - at least 50 years; body mass index (BMI) within the range of 18 - 35 kg/m2.&#xD;
&#xD;
        Patients with severe renal impairment / ESRD&#xD;
&#xD;
          -  Severe renal impairment (clinically significantly abnormal creatinine and creatinine&#xD;
             clearance (15mL/min/1.73m2≤eGFR&lt;30mL/min/1.73m2) or ESRD on hemodialysis.&#xD;
&#xD;
          -  Sitting vital signs should be within the following ranges:&#xD;
&#xD;
          -  oral body temperature between 35.0-37.5 °C&#xD;
&#xD;
          -  systolic blood pressure, 110 to 170 mm Hg&#xD;
&#xD;
          -  diastolic blood pressure, 60 to 105 mm Hg&#xD;
&#xD;
          -  pulse rate, 45 - 100 bpm&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
          -  eGFR &gt; 90mL/min/1.73m2;&#xD;
&#xD;
          -  matching in race, age (±10 years), gender, BMI (±15%) to a subject with renal&#xD;
             impairment&#xD;
&#xD;
          -  Subject must be in good health.&#xD;
&#xD;
          -  Sitting vital signs should be within the following ranges:&#xD;
&#xD;
          -  oral body temperature between 35.0-37.5 °C&#xD;
&#xD;
          -  systolic blood pressure, 100 to 150 mm Hg&#xD;
&#xD;
          -  diastolic blood pressure, 60 to 95 mm Hg&#xD;
&#xD;
          -  pulse rate, 50 to 100 bpm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
          -  History of clinically significant ECG abnormalities at Screening or Baseline.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Women of child-bearing potential unless they are using highly effective methods of&#xD;
             contraception during dosing of study treatment.&#xD;
&#xD;
          -  Sexually active males (incl. vasectomized men) must use a condom during intercourse&#xD;
             while taking drug and for 2 weeks after stopping study medication.&#xD;
&#xD;
          -  Recent (within the last three years) and/or recurrent history of autonomic dysfunction&#xD;
             (e.g., recurrent episodes of fainting, palpitations, etc.).&#xD;
&#xD;
        Patients with severe renal impairment / ESRD:&#xD;
&#xD;
          -  Presence of any non-controlled and clinically significant disease, surgical or medical&#xD;
             condition that could affect the study outcome or that would place the patient at undue&#xD;
             risk as judged by the investigator.&#xD;
&#xD;
          -  Hemoglobin levels below 9.0 g/dL at screening and baseline, other laboratory&#xD;
             parameters at screening and baseline outside acceptable limits .&#xD;
&#xD;
          -  Treatment with any cytostatic drug or autonomic alpha blocker.&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  Use of any prescription drugs (other than hormonal contraception, herbal supplements,&#xD;
             within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC)&#xD;
             medication, dietary supplements (vitamins included) within two (2) weeks prior to&#xD;
             initial dosing.&#xD;
&#xD;
          -  History or presence of any disease, surgical or medical condition of any major system&#xD;
             organ class considered clinically significant by the investigator.&#xD;
&#xD;
          -  Laboratory parameter at screening and baseline outside of normal limits. For small&#xD;
             deviations which could be attributed to the characteristics of the subjects (e.g. age)&#xD;
             it will be to the discretion of the investigator to consider them as exclusive or not.&#xD;
&#xD;
          -  A positive Hepatitis B surface antigen or Hepatitis C test result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grunstadt</city>
        <zip>D-67269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13044</url>
    <description>Results for CRLX030A2102 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal disease</keyword>
  <keyword>renal impairment</keyword>
  <keyword>End stage renal disease</keyword>
  <keyword>Healthy volunteer</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

